SURVEILLANCE CREDIT RATING REPORT LILLIAN PHARMACEUTICALS LIMITED

Ref. no.: FR/2022/026306



Report Contents:

Particulars	Page
Rating Rationale	01
Corporate Profile	02
Brief About Key Sponsors of the Company	02
Corporate Management	02
Business Analysis	02
Risk Factor Analysis	04
Rating Observations	06

Project Cost:

	Tk. in million			
Particulars	Cost			
Land & Land Development	45.11			
Building & Civil Works	155.58			
Imported Machinery and Equipment	34.25			
Local Machinery and Equipment	40.34			
Erection & Installation	1.90			
Security Deposit	0.60			
Furniture, Fixture & Equipment	0.59			
Vecicles	8.60			
Pre Operation Expenses	1.60			
TOTAL PROJECT COST	288.59			

	Long Term Rating		Date of Declaration			Date of Expiration			
Project Rating	BBB3 (Indicative)*			11 October	2022		04 Ap	ril 2023	
Methodolog	gy: Corporate	rating	methodolo	gy published	on	the	WCRCL	website	at

www.wasocreditrating.com

RATING RATIONALE

WCRCL has reaffirmed "BBB3 (Indicative)" (pronounced Triple B Three Indicative) in the long term to Lillian Pharmaceuticals Limited (hereinafter referred as "LPL" or "The Project") based on both relevant qualitative and quantitative information up to date of rating declaration. The rating reflects that LPL is subject to medium credit risk. This is considered to be medium grade and as such may possess certain speculative characteristics.

Lillian Pharmaceuticals Limited is rated in investment grade is subject to medium credit risk due to favorable condition regarding market outlook, management experience, land procurement, credibility, and locational advantage. Earlier mentioned variables are considered positive factors while assigning the rating, because market outlook of pharmacy industry favorable in Bangladesh. Project cost structure revealed low portion of debt may expose low risk in response to equity investment. The company is enjoying Project Loan of Tk. 25.00 million, outstanding as on 29.09.2022 was Tk. 20.55 Million. Specific L/C and another HPSM facility is not disbursed yet. Considering all the favorable measures and susceptibility of negative outcome this project has assigned investment grade for next six month period.

This rating may be revised subject to credibility of the sponsors, successful implementation and debt proportion in line with the Sponsor's equity investment or changes in any macro factors along with micro factors in the economy.

However, the ratings are constrained by relatively low leverage, risk associated with arranging project loan and working capital for the project, and risk associated with project implementation.

Ummay Fatema fatema@wasocreditrating.com

Md. Al Amin Jewel jewel@wasocreditrating.com